Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening hyperinflammatory condition where the immune system overreacts, attacking healthy tissues, and causing severe organ damage. It is most often triggered by malignancies (mHLH), infections, rheumatological diseases, or other…

Secondary hemophagocytic lymphohistiocytosis (sHLH) is a rare, life-threatening hyperinflammatory syndrome characterized by dysregulated immune cell function in response to a strong antigenic trigger – most commonly malignancies (mHLH), infections, or autoimmune diseases. The underlying…

ELA026 is a first-in-class human monoclonal antibody directed against signal regulatory protein (SIRP) α/β1/γ and is under clinical investigation in secondary hemophagocytic lymphohistiocytosis (sHLH). sHLH is a life-threatening hyperinflammatory condition caused by failure to…

Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening syndrome of excessive immune activation. The disease is associated with a massive systemic inflammatory response requiring immediate and aggressive treatment. Secondary HLH (sHLH) is triggered…